



Euronanoforum– 12th June 2019, Bucharest



SAFE-N-MEDTECH



Safety Testing In The Life Cycle Of Nanotechnology-enabled
Medical Technologies for Health



This project has received funding from the European Union's Horizon 2020 research and innovation programme under **grant agreement No 814607**




Project description:

SAFE-N-MEDTECH OITB aims to contribute to the full deployment of the potential of innovative medical technologies based on nanotech.

The project has started in April 2019

Our OITB will aim to cover all the necessary steps across the value chain to get medical (**nano-enabled**) innovations to the market

Nano-enabled medical technologies possess special features highlighted in the new MDs regulation






Surgx fw) #Vroxwlrq vOWhw#F dvhv:


The OITB will be fully functional after the 4 years Innovation action, with the aim to serve as a single entry point for SMEs, spin offs, research teams and industries.

The OITB is the product itself

Our OITB will be tested and refined using four test cases, products which will benefit from the OITB services:




<p>Iron Oxide Nanoparticles (14-20 nm)</p> <p>41-48 C</p> <p>AMF</p> <p>NOCANTHER</p>	<p>μHA-COATING TRAUMA IMPLANTS</p>
<p>The blood leaves marks in the non-treated area</p> <p>TREATED AREA</p> <p>NON-TREATED AREA</p> <p>MED-T-COAT</p>	<p>HELIA BIOMONITORING</p>





Euronanoforum– 12th June 2019, Bucharest





Euronanoforum– 12th June 2019, Bucharest




TEAM



COORDINATION/TECHNICAL
MANAGEMENT



TECHNOLOGY ASSESSMENT



CHARACTERIZATION



PRECLINICAL RESEARCH



CLINICAL RESEARCH



REGULATORY&HTA



TEAM



MANUFACTURING



stryker




TEST CASES DEVELOPERS



stryker

MEDICAL TECHNOLOGIES
INNOVATION HUB



João Lobo Antunes



DISSEMINATION-SMES
ENGAGEMENT






Euronanoforum– 12th June 2019, Bucharest



P dunhwE dvh# #F dhqw Hqjdjhp hqw

“A regional approach”+ “an open call”



“+ international clients”





From show to Dg yd qwdjh / Expected Revenues:

- Single entry point means easy access for SMEs and start ups
- Technology assessment allows the design of the adequate testing program avoiding extra costs and simplifying the process
- Reduced time to market due to HTA and regulatory advice from the beginning and with the guiding of the DSS
- Prototyping and fabrication in certified production facilities (ISO 13485-not easy for nano enabled MDs)
- Access to clinical sites for clinical research




- *Unique expertise, gained at EU level, in a challenging technology landscape (nanotech Health applications).*



Expected Revenues:

In 2016, more than 12,200 patent applications were filed with the EPO in the field of MTs still more than any other sector in Europe

The European Medical Technology market in 2016 is estimated at roughly €110 billion. A considerable amount of the mentioned MTs could include nanotechnology, being a business opportunity for the OITB. Nanotechnology in MD Market was valued at around \$5 Billion in 2014 and expected to reach around \$8.5 Billion by 2019 with a Compound Annual Growth Rate of around 11-12% during the forecast period 2014-2019



The OITB will offer tailor-made payment possibilities for clients: from pure payment for services to royalty-based funding and “flat rates” for interested clients



Frqfævlrq:

The new MDs regulation imposes more strict testing and validation requirements for medical technologies, with specific issues for nano-enabled MTs

Safe-N-Medtech OITB will be a reliable partner to help and accompany developers from Proof of Concept to markets



Euronanoforum– 12th June 2019, Bucharest



THANKS FOR YOUR ATTENTION

Forwarded V:

Technical & Scientific Manager: Angel del Pozo
angel.delpozo@keralty.com
+34 697106205

WP 4 leader: Oihane Ibarrola
oihane.ibarrola@keralty.com